Scheme
Rec.INN
CAS registry number (Chemical Abstracts Service)
0017737-65-4
Chemical Formula
C13-H11-Cl-N2-O2
Molecular Weight
262
Therapeutic Categories
Analgesic, antipyretic and anti-inflammatory agent
Non-steroidal anti-inflammatory drug, NSAID
Chemical Name
3-Pyridinecarboxylic acid, 2-[(3-chloro-2-methylphenyl)amino]-
Foreign Names
- Clonixinum (Latin)
- Clonixin (German)
- Clonixine (French)
- Clonixino (Spanish)
Generic Names
- Clonixin (OS: USAN)
- CBA 93626 (IS)
- Sch 10304 (IS: Schering)
- R 173 IX (IS)
Brand Names
- Clonix
Janssen, Portugal - Dorixyl
Master, Peru - Algimate
Jaba, Portugal - Blonax
Mintlab, Chile - Celex
Farmo Quimica, Chile - Clonalgin
Chemopharma, Chile - Clonix
Farmacéutica, Peru - Clonixil
Richmond, Argentina - Clonixin
Jin Yang Pharm, Vietnam - Clonixinato de lisina Duncan
Duncan, Argentina - Clonixinato de lisina Lazar
Lazar, Argentina - Clonixinato de lisina
Biosano, Chile; Mintlab, Chile; Sanderson, Chile - Colmax
Andromaco, Chile - Dentagesic
Maver, Chile - Dolalgial
Sanofi-Aventis S.A., Spain - Dolamin
Farmoquimica, Brazil - Dolex
Ivax, Argentina - Dolorfin
Bolivar Farma, Peru - Donodol
Armstrong, Mexico - Dorix
Delfarma, Peru - Dorixina
Roemmers, Argentina; Roemmers, Peru; Roemmers, Venezuela; Siegfried, Mexico - Espasmokolic (Clonixin and Pargeverine)
Sherfarma, Peru - Espasmosedil (Clonixin and Pargeverine)
Markos, Peru - Firac
Grossman, Mexico - Laboxina
Keyfarm, Peru - Lafigesic
Recalcine, Chile - Ledosin
Korea Arlico Pharm, Vietnam - Libralgen
AC Farma, Peru - Lisina Clonixinato
Caferma, Peru - Medigesic
Maver, Chile - Nefersil
Pharma Investi, Chile - Norzonol
Drag Pharma, Chile - Prestodol
Rayere, Mexico - Sedepron
Chinoin, Mexico - Traumicid
Sanofi-Pasteur, Chile
International Drug Name Search
Glossary
IS | Inofficial Synonym |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
Click for further information on drug naming conventions and International Nonproprietary Names.
No comments:
Post a Comment